DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Contribución de congreso (ConferenceOutput)
Antisense oligonucleotide reduction of human alpha-synuclein accumulation in dopamine and serotonin neurons prevents early dysfunctions in a mouse model of Parkinson's disease
Trabajo presentado en el Alpha-synuclein & Parkinson’s disease Conference: Lessons from the past 20 years, celebrado en la Universitat de Barcelona los días 11 y 12 de mayo de 2017, Pathological changes in end-state of Parkinson’s disease (PD) are well characterized. However,
there is an urgent need to identify early functional changes to develop new therapeutic strategies
stopping the development of the illness. α-Synuclein is a protein accumulating in the brain of
PD patients. We generated a mouse model overexpressing wild-type human-α-synuclein in
dopamine-DA or serotonin-5-HT neurons of substantia nigra-(SNc) and raphe nuclei-(RN),
respectively. These mice showed increased human-α-synuclein mRNA levels in the ipsilateral
SNc and RN, without loss tyrosine hydroxylase-(TH)-positive or tryptophan hydroxylase-
(TPH2)-positive neurons. Moreover, reduced DA and 5-HT release with development of αsynuclein-positive axonal swelling in striatum were found in these mice. In addition, AAV5
mice exhibited motor deficits at 8 weeks post-infection into SNc and depressive-like behaviors
at 4 weeks post-infection into RN. Here, we evaluated whether reducing human-α-synuclein
expression in the mesencephalic nuclei prevented early dysfunctions in the AAV5 model. We
used a conjugated antisense oligonucleotide targeting intracellular human-α-synuclein
(ASO1337) selectively in DA and 5-HT neurons. Mice overexpressing human-α-synuclein in
the SNc/VTA or RN were treated intracerebroventricularly with vehicle, nonsense ASO
sequence (ASO1227) or ASO1337 (30 or 100μg/day) during 28 days using osmotic minipumps
implanted subcutaneously. ASO1337 reduced dose-dependent the human-α-synuclein mRNA
levels (ASO1337 30μg/day: 60,21%±15.93; ASO1337 100μ/day: 46.71%±8.63, respect vehicle)
whereas endogenous α-synuclein expression remained unaltered. Immunohistochemistry shows
the reduction of human-α-synuclein protein density (vehicle: 245,56%±5.32: ASO1337
30μg/day: 177.7%±7.65; ASO1337 100μ/day: 173%±2.93, respect contralateral side).
Furthermore, recovery of striatal DA release was achieved by reduction of human-α-synuclein
expression in SNc/VTA. Our study indicated that the reduction of intracellular α-synuclein
accumulation selectively in DA and 5-HT neurons using ASO molecules represents an optimal
PD therapy., Spanish Ministry of Economy and Competitiveness, INNPACTO Subprogram IPT2012-1208-300000 and Retos-Colaboración Subprogram RTC-2014-2812-1; Instituto de Salud
Carlos III PI13/01390 co-financed by the European Regional Development Fund “A way to
build Europe”., Peer reviewed